Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco
October 14, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
Opthea to Present at the Ophthalmology Innovation Summit in San Francisco
October 03, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
Opthea Presents Positive Data from OPT-302 Phase 2b Wet AMD Trial at EURETINA Congress
September 06, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that new...
Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA
September 04, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that...
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
August 06, 2019 18:58 ET
|
Opthea Limited
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis® Company to Host Conference Call Today at 9:00 AM AEST7:00PM EDT (Tuesday, August 6th U.S)-Dial-in details posted at...
Opthea to Host Investor Teleconference
August 05, 2019 13:08 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2b clinical trial of OPT-302 in combination...
Opthea’s Patent Application Covering OPT-302 to be Granted by European Patent Office
July 30, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 30, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the European Patent Office (EPO) has issued a “Notice of Intention to Grant” in relation...
Opthea Completes Final Patient Visit in Phase 2b Wet AMD Clinical Trial
May 15, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, May 15, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, announced today...
Opthea’s Phase 2b Trial in Wet AMD Advances with a Second Positive Independent Safety Committee Recommendation
March 07, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the independent Data and Safety Monitoring Board (DSMB) for the Company’s ongoing Phase...
Opthea Granted Japanese Patent Covering OPT-302
January 29, 2019 11:25 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce the grant of Japanese Patent Number 6408492 covering its OPT-302 soluble VEGFR-3 (sVEGFR-3)...